Published in Medical Device Business Week, November 15th, 2006
The U.S. FDA approved trial is designed to demonstrate Arctic Front's clinical and therapeutic effectiveness in treating atrial fibrillation (AF).
The patient was enrolled by Dr. Kevin Wheelan and treated at the Baylor Medical Center in Dallas, Texas. The procedure was considered an acute success. There were no safety concerns noted, including no reports of phrenic nerve injury, thrombosis, or stroke.
"We consider the enrollment and successful treatment of the first patient an important...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.